Literature DB >> 24702741

Prognostic models predicting survival of patients with brain metastases: integration of lactate dehydrogenase, albumin and extracranial organ involvement.

C Nieder1, K Marienhagen2, A Dalhaug3, G Aandahl4, E Haukland4, A Pawinski4.   

Abstract

AIMS: To explore the role of expanded assessment of metastatic extracranial organ involvement, as well as albumin and lactate dehydrogenase (LDH), i.e. surrogates of disease extent, in survival prediction models for patients with brain metastases.
MATERIALS AND METHODS: A retrospective analysis of 189 patients treated with whole brain radiotherapy was carried out. Uni- and multivariate analyses included recursive partitioning analysis classes, basic score for brain metastases and diagnosis-specific graded prognostic assessment (DS-GPA).
RESULTS: Elevated LDH correlated significantly with extracranial organ involvement, low albumin with primary tumour type and primary tumour control. Elevated LDH, low albumin and a combination of both correlated significantly with overall survival. LDH, albumin and the number of extracranial organs involved (none, one, two or more harbouring metastases) were independent prognostic factors in multivariate analyses (if added to the three established scores mentioned above and also if added to individual parameters such as age, performance status, etc.). A combination of these three new prognostic factors predicted very short survival (median 0.7 months if all three were present).
CONCLUSION: We have previously defined patient groups in whom foregoing radiotherapy was unlikely to compromise survival. These were patients with a DS-GPA score of 0-1.5 points and age ≥75 years or Karnofsky performance status ≤50 or uncontrolled primary tumour with extracranial metastases to at least two organs. Patients with a combination of three new adverse features (elevated LDH plus low albumin plus extracranial metastases to at least two organs) might also be considered for best supportive care. Furthermore, it appears warranted to study whether scores such as DS-GPA can be optimised by integrating information on these three parameters.
Copyright © 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Albumin; best supportive care; brain metastases; lactate dehydrogenase; prognostic factors; radiotherapy

Mesh:

Substances:

Year:  2014        PMID: 24702741     DOI: 10.1016/j.clon.2014.03.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  12 in total

1.  Palliative Radiotherapy During the Last Month of Life: Have COVID-19 Recommendations Led to Reduced Utilization?

Authors:  Carsten Nieder; Ellinor C Haukland; Bard Mannsaker; Rosalba Yobuta
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Triple Isotope Effects Support Concerted Hydride and Proton Transfer and Promoting Vibrations in Human Heart Lactate Dehydrogenase.

Authors:  Zhen Wang; Eric P Chang; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2016-11-04       Impact factor: 15.419

3.  Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery.

Authors:  Carsten Nieder; Bård Mannsåker; Rosalba Yobuta
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

4.  Protein Conformational Landscapes and Catalysis. Influence of Active Site Conformations in the Reaction Catalyzed by L-Lactate Dehydrogenase.

Authors:  Katarzyna Świderek; Iñaki Tuñón; Sergio Martí; Vicent Moliner
Journal:  ACS Catal       Date:  2015-01-07       Impact factor: 13.084

5.  Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research.

Authors:  Carsten Nieder; Astrid Dalhaug; Ellinor Haukland; Bård Mannsåker; Adam Pawinski
Journal:  Tumour Biol       Date:  2015-03-24

6.  Short Survival Time after Palliative whole Brain Radiotherapy: Can We Predict Potential Overtreatment by Use of a Nomogram?

Authors:  Carsten Nieder; Jan Norum; Mandy Hintz; Anca L Grosu
Journal:  J Cancer       Date:  2017-06-01       Impact factor: 4.207

7.  Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).

Authors:  Carsten Nieder; Mandy Hintz; Oliver Oehlke; Angelika Bilger; Anca L Grosu
Journal:  Radiat Oncol       Date:  2017-06-26       Impact factor: 3.481

8.  External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors.

Authors:  Victor Lewitzki; Rainer J Klement; Sebastian Hess; Rebekka Kosmala; Carsten Nieder; Michael Flentje
Journal:  Clin Transl Radiat Oncol       Date:  2019-02-27

9.  Decision support systems for incurable non-small cell lung cancer: a systematic review.

Authors:  D Révész; E G Engelhardt; J J Tamminga; F M N H Schramel; B D Onwuteaka-Philipsen; E M W van de Garde; E W Steyerberg; E P Jansma; H C W De Vet; V M H Coupé
Journal:  BMC Med Inform Decis Mak       Date:  2017-10-02       Impact factor: 2.796

10.  LabBM Score and Extracranial Score As New Tools for Predicting Survival in Patients with Brain Metastases Treated with Focal Radiotherapy.

Authors:  Carsten Nieder; Rosalba Yobuta; Bård Mannsåker
Journal:  Cureus       Date:  2020-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.